Supplementary Materials and Methods; Supplementary Figures S1-S5; and Supplementary Tables S1-S5 from αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4

The files contain (1) Supplementary Materials and Methods for αVβ3 expression analysis, autoradiography and histological analysis, and hematology and hepatorenal function; (2) Supplementary Tables S1-S5; and (3) Supplementary Figures S1-S5. Table S1â^'Effects of 37 MBq (1 nmole) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 {plus minus} GF/Lys on hepatorenal functions of U87MG tumor-bearing mice; Table S2â^'Blood cell counts of U87MG tumor-bearing mice at various time points post-injection of 37 MBq (1 nmole) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 {plus minus} GF/Lys; Table S3â^'Blood cell counts of U87MG tumor-bearing mice at various time points after single dose administrations of 37 and 74 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Table S4â^'Effects of 74 MBq (2 nmole) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 + GF/Lys on hepatorenal functions of normal mice; Table S5â^'Human absorbed doses extrapolated from the biodistribution data of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in U87MG tumor-bearing mice; Figure S1â^'The treatment outcomes of radiotherapy with 37 MBq (1 nmole) of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Figure S2â^'Toxicity studies in normal mice that were injected with 74 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Figure S3â^'Preliminary study of U87MG tumors excised at day 13 p.i. of 37 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4 for the changes in microvasculature; Figure S4â^'Positive correlation between the tumor volume and the corresponding WBC in U87MG tumor-bearing mice; Figure S5â^'Biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 at various peptide doses (0.005â^'10 nmole) in U87MG tumor-bearing mice.